Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Kuros Biosciences (CSBTF) Stock Price & Analysis

15 Followers

CSBTF Stock Chart & Stats

$24.09-$0.10(-0.41%)
At close: 4:00 PM EST
$22$24$26Aug 17Sep 4Sep 8Oct 22Oct 29Nov 12
Day’s Range
$24.09 - $24.09
52-Week Range
$18.40 - $40.63
Previous Close
$24.19
Volume
N/A
Average Volume (3M)
72
Market Cap
$958.36M
Enterprise Value
$776.03M
Total Cash (Recent Filing)
$7.85M
Total Debt (Recent Filing)
$11.01M
Price to Earnings (P/E)
108.8
Beta
0.72
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Scale And Profitability

The sharp revenue expansion, very high gross margin, and 2025 move into operating and net profitability indicate improving commercial scale. Although earnings remain early, this combination can support reinvestment and stronger earnings power if growth and pricing remain durable over coming quarters.

Conservative Balance Sheet

Very low leverage gives Kuros financial flexibility while it expands commercialization and manufacturing capacity. Limited debt reduces interest and refinancing pressure, allowing more operating resources to support clinical programs, market development, and investments in future production capability.

Commercial Expansion And Adoption

Broader distributor coverage, rising surgeon utilization, and substantial patient experience suggest the product is gaining lasting commercial traction rather than relying solely on a narrow customer base. Greater adoption can strengthen market position and create a wider foundation for future revenue growth.

Bears Say

Weak Cash Conversion

Negative operating and free cash flow despite improved earnings shows that accounting profitability has not yet translated into dependable cash generation. If this persists, Kuros may have less internally generated funding for clinical development, capacity expansion, and other strategic investments.

Thin And Recently Established Profitability

The profitability inflection is encouraging, but thin margins provide limited protection if growth slows, costs rise, or pricing weakens. Because Kuros only recently moved out of substantial losses, sustained earnings quality and margin durability still need to be demonstrated.

Manufacturing Ramp And Working-capital Pressure

Building U.S. manufacturing capacity and funding transformation costs can temporarily absorb cash and dilute margins before the expected operating benefits arrive. Elevated receivables also increase dependence on timely collections, creating execution and liquidity sensitivity during the expansion phase.

Kuros Biosciences News

CSBTF FAQ

What was Kuros Biosciences’s price range in the past 12 months?
Kuros Biosciences lowest stock price was $18.40 and its highest was $40.63 in the past 12 months.
What is Kuros Biosciences’s market cap?
Kuros Biosciences’s market cap is $958.36M.
When is Kuros Biosciences’s upcoming earnings report date?
Kuros Biosciences’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 109 days.
How were Kuros Biosciences’s earnings last quarter?
Kuros Biosciences released its earnings results on Aug 13, 2026. The company reported $0.073 earnings per share for the quarter, beating the consensus estimate of $0.072 by $0.001.
Is Kuros Biosciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kuros Biosciences pay dividends?
Kuros Biosciences does not currently pay dividends.
What is Kuros Biosciences’s EPS estimate?
Kuros Biosciences’s EPS estimate is 0.10.
How many shares outstanding does Kuros Biosciences have?
Kuros Biosciences has 39,826,588 shares outstanding.
What happened to Kuros Biosciences’s price movement after its last earnings report?
Kuros Biosciences reported an EPS of $0.073 in its last earnings report, beating expectations of $0.072. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kuros Biosciences?
Currently, no hedge funds are holding shares in CSBTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology